Summary of Longeveron's Q2 2026 Earnings Call

1Key Financial Results and Metrics

Revenues: $0.3 million for Q2 2026, a decrease of $29,000 (10%) compared to Q2 2025, primarily due to the absence of contract manufacturing revenue.

Expenses:

General and Administrative: $3.2 million, up from $2.6 million in Q2 2025 (23% increase), driven by higher legal and personnel costs.

Research and Development: $3.2 million, an increase of $200,000 (7%) from Q2 2025, reflecting higher clinical trial expenses.

Net Loss: $6.1 million for Q2 2026, compared to $5 million in Q2 2025, a 22% increase.

Cash Position: $10.1 million as of June 30, 2026, expected to fund operations into Q4 2026.

2Strategic Updates and Business Highlights

Longeveron is focused on its stem cell therapy, Laromestrocel, targeting four indications: Hypoplastic Left Heart Syndrome (HLHS), Alzheimer's disease, pediatric dilated cardiomyopathy, and aging-related frailty.

The company is preparing for the ELPIS II Phase 2b trial data readout for HLHS, expected in mid-September 2026.

Longeveron has been recognized as a finalist in the XPRIZE HealthSpan Competition, receiving a $1 million award for its promising data in aging-related frailty.

The company aims to explore partnerships for development and commercialization to leverage resources and expertise.

3Forward Guidance and Outlook

Anticipation of positive data from the ELPIS II trial could lead to partnership discussions and potential regulatory submissions for a Biologics License Application (BLA).

The company is optimistic about its ability to navigate regulatory pathways, especially with the potential for priority review vouchers.

Plans for a Phase 2 trial in pediatric dilated cardiomyopathy are in preparation, with an IND application already effective.

4Bad News, Challenges, or Points of Concern

The decrease in revenue and increasing net loss may raise concerns about financial sustainability.

The absence of contract manufacturing revenue indicates potential challenges in revenue diversification.

Regulatory uncertainties remain, particularly regarding the ELPIS II trial endpoints and the need for FDA alignment on the statistical analysis plan (SAP).

Delays in trial timelines were noted, specifically a shift from an August to a September data readout, which could impact investor confidence.

5Notable Q&A Insights

Management expressed confidence in the regulatory submission timeline post-ELPIS II data, contingent on positive results.

Discussions regarding commercial scale-up and pricing strategies are ongoing with potential partners, suggesting proactive engagement with the market.

The FDA's willingness to work with Longeveron on exploratory endpoints was highlighted, indicating a collaborative approach to regulatory challenges.

The company is collecting long-term survival data for patients, which may support future BLA submissions, even if primary endpoints are not met. Overall, Longeveron is at a pivotal moment with promising clinical developments but faces financial and regulatory challenges that need to be addressed as it moves forward.